Jeong-Gyun Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeong-Gyun Lee has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Kyeong Soo Kim
Department of Pharmaceutical Engineering, Gyeongsang National University, Jinju, Republic of Korea
11 shared publications - Tae-Han Yun
Department of Pharmaceutical Engineering, Gyeongsang National University, 33 Dongjin-ro, Jinju 52725, Republic of Korea
5 shared publications - Jung Hyun Cho
Department of Pharmaceutical Engineering, Dankook University, Cheonan, Republic of Korea
4 shared publications - Kyu Ho Bang
Department of Pharmaceutical Engineering, Gyeongsang National University, 33 Dongjin-ro, Jinju 52725, Republic of Korea
3 shared publications - Chul Ho Kim
Department of Pharmaceutical Engineering, Gyeongsang National University, 33 Dongjin-ro, Jinju 52725, Republic of Korea
2 shared publications - Moon Jung Kim
Department of Pharmaceutical Engineering, Gyeongsang National University, 33 Dongjin-ro, Jinju 52725, Republic of Korea
2 shared publications
Latest Publications
- Open Access
Development and Optimization of an HPMC/TPGS-Based Apixaban Amorphous Solid Dispersion for Enhanced Supersaturation and Oral Absorption
An apixaban (APX) amorphous solid dispersion (ASD) containing hydroxypropyl methylcellulose (HPMC) and D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) was prepared by spray drying to improve solubility and oral exposure. Screening identified HPMC for supersaturation maintenance and TPGS for apparent solubilization. A central composite design optimized their ratios using five responses: supersaturation solubility, 30-min kinetic solubility, kinetic solubility area under the curve (AUC), particle size, and polydispersity index (PDI). The optimized APX/HPMC/TPGS ratio was 1:3.93:0.85 (w/w/w), with a composite desirability of 0.8491 (on a scale from 0 to 1). Compared with crystalline APX, the optimized ASD increased supersaturation solubility, 30-min kinetic solubility, and kinetic solubility AUC 4.04-, 5.47-, and 8.10-fold, respectively. The dispersed formulation exhibited a particle size of 203.4 ± 17.3 nm and PDI of 0.246 ± 0.018. PXRD and DSC supported predominantly amorphous APX, while electron microscopy and DLS supported nanosized colloidal particle formation. The optimized ASD also maintained higher kinetic solubility in fasted-state simulated intestinal fluid than crystalline and amorphous APX. In rats, Cmax, AUC0–24, and AUC0–inf increased by 2.46-, 3.04-, and 2.80-fold, respectively, versus crystalline APX.
Open AccessDevelopment and Optimization of an HPMC/TPGS-Based Apixaban Amorphous Solid Dispersion for Enhanced Supersaturation and Oral Absorption
An apixaban (APX) amorphous solid dispersion (ASD) containing hydroxypropyl methylcellulose (HPMC) and D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) was prepared by spray drying to improve solubility and oral exposure. Screening identified HPMC for supersaturation maintenance and TPGS for apparent solubilization. A central composite design optimized their ratios using five responses: supersaturation solubility, 30-min kinetic solubility, kinetic solubility area under the curve (AUC), particle size, and polydispersity index (PDI). The optimized APX/HPMC/TPGS ratio was 1:3.93:0.85 (w/w/w), with a composite desirability of 0.8491 (on a scale from 0 to 1). Compared with crystalline APX, the optimized ASD increased supersaturation solubility, 30-min kinetic solubility, and kinetic solubility AUC 4.04-, 5.47-, and 8.10-fold, respectively. The dispersed formulation exhibited a particle size of 203.4 ± 17.3 nm and PDI of 0.246 ± 0.018. PXRD and DSC supported predominantly amorphous APX, while electron microscopy and DLS supported nanosized colloidal particle formation. The optimized ASD also maintained higher kinetic solubility in fasted-state simulated intestinal fluid than crystalline and amorphous APX. In rats, Cmax, AUC0–24, and AUC0–inf increased by 2.46-, 3.04-, and 2.80-fold, respectively, versus crystalline APX.
- Open Access
- 4 November 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (11) , 1433
Development and Optimization of Tacrolimus-Loaded Solid Lipid Nanoparticle Gels Using a Box–Behnken Design: Comparison of Three Lipid Matrices and In Vivo Evaluation
Background/Objectives: Tacrolimus has poor aqueous solubility and limited skin permeation, necessitating formulation strategies for effective topical therapy. This study aimed to develop tacrolimus-loaded solid lipid nanoparticles (SLNs) and an SLN-gel, comparing optimized SLNs prepared with three lipids—Compritol 888 ATO (C888), Compritol HD5 ATO (CHD5), and Stearic acid (St.a). Methods: Each SLN was optimized via Box–Behnken design (BBD) using factors X1 (lipid amount), X2 (surfactant amount), and X3 (homogenization speed). Morphological analysis was conducted using SEM and TEM, while the solid-state properties were evaluated by XRD and FT-IR. In vitro drug release was assessed using the dialysis bag method, and permeation was evaluated using Franz diffusion cells. The SLNs showing the highest cumulative permeation with a consistent release profile were tested in a 1-chloro-2,4-dinitrobenzene (DNCB)-induced atopic dermatitis mouse model. Results: Optimized SLNs obtained from the BBD demonstrated particle sizes of 275.8, 190.9, 308.9 nm, PDIs of 0.35, 0.26, 0.14, zeta potentials of −15.2, −12.9, −24.0 mV, and encapsulation efficiencies of 84.6, 91.8, 92.5% for C888, CHD5, and St.a, respectively. In dialysis-bag studies, all SLNs showed higher cumulative release than drug solution and Protopic® 0.1%. SEM/TEM revealed spherical morphology, while FT-IR/XRD confirmed drug incorporation within the lipid matrix. Franz diffusion showed higher permeation than API-gel and Protopic® 0.1%, ranked St.a > C888 > CHD5, with 48 h cumulative amounts of 127.2, 96.8, 87.5 μg/cm2. The St.a-SLN-gel significantly improved atopic dermatitis lesions in the DNCB-induced mouse model in vivo (score 14.5→1.75, n = 6, p < 0.001). Conclusions: Box–Behnken optimization produced an SLN-gel surpassing existing formulations in release, permeation, and in vivo efficacy, demonstrating tunable performance via lipid selection and offering a reproducible, translatable approach for topical tacrolimus.
- 4 November 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (11) , 1433
Open AccessDevelopment and Optimization of Tacrolimus-Loaded Solid Lipid Nanoparticle Gels Using a Box–Behnken Design: Comparison of Three Lipid Matrices and In Vivo Evaluation
Background/Objectives: Tacrolimus has poor aqueous solubility and limited skin permeation, necessitating formulation strategies for effective topical therapy. This study aimed to develop tacrolimus-loaded solid lipid nanoparticles (SLNs) and an SLN-gel, comparing optimized SLNs prepared with three lipids—Compritol 888 ATO (C888), Compritol HD5 ATO (CHD5), and Stearic acid (St.a). Methods: Each SLN was optimized via Box–Behnken design (BBD) using factors X1 (lipid amount), X2 (surfactant amount), and X3 (homogenization speed). Morphological analysis was conducted using SEM and TEM, while the solid-state properties were evaluated by XRD and FT-IR. In vitro drug release was assessed using the dialysis bag method, and permeation was evaluated using Franz diffusion cells. The SLNs showing the highest cumulative permeation with a consistent release profile were tested in a 1-chloro-2,4-dinitrobenzene (DNCB)-induced atopic dermatitis mouse model. Results: Optimized SLNs obtained from the BBD demonstrated particle sizes of 275.8, 190.9, 308.9 nm, PDIs of 0.35, 0.26, 0.14, zeta potentials of −15.2, −12.9, −24.0 mV, and encapsulation efficiencies of 84.6, 91.8, 92.5% for C888, CHD5, and St.a, respectively. In dialysis-bag studies, all SLNs showed higher cumulative release than drug solution and Protopic® 0.1%. SEM/TEM revealed spherical morphology, while FT-IR/XRD confirmed drug incorporation within the lipid matrix. Franz diffusion showed higher permeation than API-gel and Protopic® 0.1%, ranked St.a > C888 > CHD5, with 48 h cumulative amounts of 127.2, 96.8, 87.5 μg/cm2. The St.a-SLN-gel significantly improved atopic dermatitis lesions in the DNCB-induced mouse model in vivo (score 14.5→1.75, n = 6, p < 0.001). Conclusions: Box–Behnken optimization produced an SLN-gel surpassing existing formulations in release, permeation, and in vivo efficacy, demonstrating tunable performance via lipid selection and offering a reproducible, translatable approach for topical tacrolimus.
- Open Access
- 2 November 2026
- Published by MDPI AG in Preprints.org
Development and Optimization of an HPMC/TPGS‐Based Apixaban Amorphous Solid Dispersion for Enhanced Supersaturation and Oral Absorption
An HPMC/TPGS-based amorphous solid dispersion (ASD) of Apixaban (APX) was developed to improve supersaturation maintenance, colloidal dispersion, and oral exposure. Screening studies showed that HPMC was the most suitable polymer for maintaining APX supersaturation, while TPGS provided the greatest solubilizing effect among the surfactants tested. The HPMC and TPGS ratios were subsequently optimized using a central composite design based on five responses: supersaturation solubility, kinetic solubility at 30 min, kinetic solubility area under the curve (AUC), particle size, and polydispersity index (PDI). The selected formulation contained HPMC and TPGS at ratios of 3.93 and 0.85 relative to APX, respectively, with a composite desirability of 0.8491. Validation of the optimized ASD yielded a supersaturation solubility of 112.1 ± 2.2 μg/mL, a 30-min kinetic solubility of 360.1 ± 4.4 μg/mL, a kinetic solubility AUC of 118545.6 ± 1053.6 μg·min/mL, a particle size of 203.4 ± 17.3 nm, and a PDI of 0.246 ± 0.018. PXRD and DSC analyses showed loss of APX crystallinity, while morphological observations by SEM and TEM, together with DLS measurements after aqueous dispersion, supported the formation of nanosized colloidal particles. The optimized ASD also maintained higher kinetic solubility in fasted-state simulated intestinal fluid (FaSSIF, pH 6.5) than crystalline and amorphous APX. For pharmacokinetic evaluation, the formulations were orally administered to rats, and plasma APX concentrations were measured. Compared with crystalline APX powder, the optimized ASD increased Cmax, AUC0–24, and AUC0–inf by 2.46-, 3.04-, and 2.80-fold, respectively. Overall, the HPMC/TPGS-based ASD improved both the dissolution-related performance and systemic exposure of APX.
- 2 November 2026
- Published by MDPI AG in Preprints.org
Open AccessDevelopment and Optimization of an HPMC/TPGS‐Based Apixaban Amorphous Solid Dispersion for Enhanced Supersaturation and Oral Absorption
An HPMC/TPGS-based amorphous solid dispersion (ASD) of Apixaban (APX) was developed to improve supersaturation maintenance, colloidal dispersion, and oral exposure. Screening studies showed that HPMC was the most suitable polymer for maintaining APX supersaturation, while TPGS provided the greatest solubilizing effect among the surfactants tested. The HPMC and TPGS ratios were subsequently optimized using a central composite design based on five responses: supersaturation solubility, kinetic solubility at 30 min, kinetic solubility area under the curve (AUC), particle size, and polydispersity index (PDI). The selected formulation contained HPMC and TPGS at ratios of 3.93 and 0.85 relative to APX, respectively, with a composite desirability of 0.8491. Validation of the optimized ASD yielded a supersaturation solubility of 112.1 ± 2.2 μg/mL, a 30-min kinetic solubility of 360.1 ± 4.4 μg/mL, a kinetic solubility AUC of 118545.6 ± 1053.6 μg·min/mL, a particle size of 203.4 ± 17.3 nm, and a PDI of 0.246 ± 0.018. PXRD and DSC analyses showed loss of APX crystallinity, while morphological observations by SEM and TEM, together with DLS measurements after aqueous dispersion, supported the formation of nanosized colloidal particles. The optimized ASD also maintained higher kinetic solubility in fasted-state simulated intestinal fluid (FaSSIF, pH 6.5) than crystalline and amorphous APX. For pharmacokinetic evaluation, the formulations were orally administered to rats, and plasma APX concentrations were measured. Compared with crystalline APX powder, the optimized ASD increased Cmax, AUC0–24, and AUC0–inf by 2.46-, 3.04-, and 2.80-fold, respectively. Overall, the HPMC/TPGS-based ASD improved both the dissolution-related performance and systemic exposure of APX.
- Open Access
Spray-Dried Inclusion Complex of Apixaban with β-Cyclodextrin Derivatives: Characterization, Solubility, and Molecular Interaction Analysis
Apixaban (APX) is a direct oral anticoagulant with low aqueous solubility and limited bioavailability. This study aimed to improve APX solubility by forming spray-dried inclusion complexes (ICs) with β-cyclodextrin (β-CD) derivatives. ICs were prepared using hydroxypropyl-β-CD (HP-β-CD), sulfobutylether-β-CD (SBE-β-CD), randomly methylated-β-CD (RM-β-CD), and heptakis(2,6-di-O-methyl)-β-CD (DM-β-CD). Complex formation (1:1 stoichiometry) was confirmed by phase solubility studies and Job’s plots. The ICs were characterized by SEM, PXRD, DSC, and FTIR, and their saturated solubility was evaluated. Molecular docking assessed host–guest interactions. Among the tested carriers, DM-β-CD exhibited the highest stability constant (KC = 371.92 M−1) and produced amorphous ICs. DM-ICs achieved the greatest solubility enhancement at all pH conditions, with a maximum solubility of 1968.7 μg/mL at pH 1.2 and ~78.7-fold increase in water compared with pure APX. Docking results supported stable inclusion with the lowest binding free energy (−8.01 kcal/mol). These findings indicate that DM-β-CD-based ICs effectively enhance APX dissolution and show potential as solubilizing carriers for oral dosage forms.
Open AccessSpray-Dried Inclusion Complex of Apixaban with β-Cyclodextrin Derivatives: Characterization, Solubility, and Molecular Interaction Analysis
Apixaban (APX) is a direct oral anticoagulant with low aqueous solubility and limited bioavailability. This study aimed to improve APX solubility by forming spray-dried inclusion complexes (ICs) with β-cyclodextrin (β-CD) derivatives. ICs were prepared using hydroxypropyl-β-CD (HP-β-CD), sulfobutylether-β-CD (SBE-β-CD), randomly methylated-β-CD (RM-β-CD), and heptakis(2,6-di-O-methyl)-β-CD (DM-β-CD). Complex formation (1:1 stoichiometry) was confirmed by phase solubility studies and Job’s plots. The ICs were characterized by SEM, PXRD, DSC, and FTIR, and their saturated solubility was evaluated. Molecular docking assessed host–guest interactions. Among the tested carriers, DM-β-CD exhibited the highest stability constant (KC = 371.92 M−1) and produced amorphous ICs. DM-ICs achieved the greatest solubility enhancement at all pH conditions, with a maximum solubility of 1968.7 μg/mL at pH 1.2 and ~78.7-fold increase in water compared with pure APX. Docking results supported stable inclusion with the lowest binding free energy (−8.01 kcal/mol). These findings indicate that DM-β-CD-based ICs effectively enhance APX dissolution and show potential as solubilizing carriers for oral dosage forms.
- Open Access
- 22 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (9) , 1230
Enhanced Efinaconazole Permeation and Activity Against Trichophyton rubrum and Trichophyton mentagrophytes with a Self-Nanoemulsifying Drug Delivery System
Background: Onychomycosis responds poorly to topical therapy, and efinaconazole (EFN) has low aqueous solubility. Methods: This study aimed to develop a 10% w/w EFN self-nanoemulsifying system (SNEDDS) with improved solubility, permeation, antifungal activity, and stability. Excipients were screened by EFN saturation solubility. An MCT oil/Solutol HS 15/Labrafil M2125 CS SNEDDS (5/75/20, w/w) was optimized via a pseudo-ternary diagram. Characterization included droplet size, PDI, and zeta potential, morphology, and drug–excipient compatibility. Solubility was measured across pH. Permeation of EFN SNEDDS vs. EFN suspension was tested by Franz diffusion cells. Antifungal activity against Trichophyton rubrum and Trichophyton mentagrophytes was assessed by paper-disc diffusion, and hyphal damage on human nails was examined by SEM. Stability was studied for six months under room, accelerated, and stress conditions. Results: The optimized SNEDDS formed sub-50 nm droplets with low polydispersity and favourable zeta potential. Solubility was maintained across pH, and cumulative permeation increased 13.6-fold versus suspension. Paper-disc assays showed larger inhibition zones at lower EFN doses. SEM on human nails revealed marked hyphal destruction. TEM confirmed spherical nanoemulsion droplets. FT-IR showed no new peaks, supporting compatibility. Particle size, PDI, zeta potential, and drug content remained stable over six months under all storage conditions. Conclusions: A 10% w/w EFN SNEDDS enhanced solubility, transungual permeation, and antifungal efficacy while maintaining robust stability, supporting its potential as an ethanol-free therapy for onychomycosis.
- 22 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (9) , 1230
Open AccessEnhanced Efinaconazole Permeation and Activity Against Trichophyton rubrum and Trichophyton mentagrophytes with a Self-Nanoemulsifying Drug Delivery System
Background: Onychomycosis responds poorly to topical therapy, and efinaconazole (EFN) has low aqueous solubility. Methods: This study aimed to develop a 10% w/w EFN self-nanoemulsifying system (SNEDDS) with improved solubility, permeation, antifungal activity, and stability. Excipients were screened by EFN saturation solubility. An MCT oil/Solutol HS 15/Labrafil M2125 CS SNEDDS (5/75/20, w/w) was optimized via a pseudo-ternary diagram. Characterization included droplet size, PDI, and zeta potential, morphology, and drug–excipient compatibility. Solubility was measured across pH. Permeation of EFN SNEDDS vs. EFN suspension was tested by Franz diffusion cells. Antifungal activity against Trichophyton rubrum and Trichophyton mentagrophytes was assessed by paper-disc diffusion, and hyphal damage on human nails was examined by SEM. Stability was studied for six months under room, accelerated, and stress conditions. Results: The optimized SNEDDS formed sub-50 nm droplets with low polydispersity and favourable zeta potential. Solubility was maintained across pH, and cumulative permeation increased 13.6-fold versus suspension. Paper-disc assays showed larger inhibition zones at lower EFN doses. SEM on human nails revealed marked hyphal destruction. TEM confirmed spherical nanoemulsion droplets. FT-IR showed no new peaks, supporting compatibility. Particle size, PDI, zeta potential, and drug content remained stable over six months under all storage conditions. Conclusions: A 10% w/w EFN SNEDDS enhanced solubility, transungual permeation, and antifungal efficacy while maintaining robust stability, supporting its potential as an ethanol-free therapy for onychomycosis.
- Open Access
- 16 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1686
Approaches for Inclusion Complexes of Ezetimibe with Cyclodextrins: Strategies for Solubility Enhancement and Interaction Analysis via Molecular Docking
This study aimed to improve the solubility of ezetimibe (EZT), which has low aqueous solubility, by preparing complexes using β-cyclodextrin (β-CD) derivatives. Phase solubility studies and Job’s plot confirmed a high apparent stability constant for EZT with β-CD and even higher constants with its derivatives, establishing a 1:1 stoichiometric ratio. The composites were prepared using spray drying over a range of molar ratios, and their physicochemical properties were evaluated using techniques such as scanning electron microscopy (SEM), powder X-ray diffraction (PXRD), and Fourier transform infrared spectroscopy (FT-IR). Saturation solubility and in vitro dissolution tests revealed that solubility increased with higher CD molar ratios. EZT/RM-β-CD inclusion complexes (ICs) and EZT/DM-β-CD ICs exhibited a similar solubility, which was greater than that of EZT/HP-β-CD ICs and EZT/SBE-β-CD ICs (where RM, DM, HP, and SEB represent H, CH3, -CH2-CHOH-CH3 and -(CH2)4-SO3Na synthetic derivatives, respectively). Most complexes, except for EZT/SBE-β-CD at 1:2 or higher ratios, showed superior solubility compared with EZT powder and commercial products. Molecular docking simulations confirmed EZT inclusion within the CD, revealing hydrogen bonds and binding energies that aligned with solubility trends. These findings suggest that EZT complexes with β-CD derivatives significantly improve solubility, highlighting their potential for developing more effective oral solid formulations for hyperlipidemia treatment.
- 16 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1686
Open AccessApproaches for Inclusion Complexes of Ezetimibe with Cyclodextrins: Strategies for Solubility Enhancement and Interaction Analysis via Molecular Docking
This study aimed to improve the solubility of ezetimibe (EZT), which has low aqueous solubility, by preparing complexes using β-cyclodextrin (β-CD) derivatives. Phase solubility studies and Job’s plot confirmed a high apparent stability constant for EZT with β-CD and even higher constants with its derivatives, establishing a 1:1 stoichiometric ratio. The composites were prepared using spray drying over a range of molar ratios, and their physicochemical properties were evaluated using techniques such as scanning electron microscopy (SEM), powder X-ray diffraction (PXRD), and Fourier transform infrared spectroscopy (FT-IR). Saturation solubility and in vitro dissolution tests revealed that solubility increased with higher CD molar ratios. EZT/RM-β-CD inclusion complexes (ICs) and EZT/DM-β-CD ICs exhibited a similar solubility, which was greater than that of EZT/HP-β-CD ICs and EZT/SBE-β-CD ICs (where RM, DM, HP, and SEB represent H, CH3, -CH2-CHOH-CH3 and -(CH2)4-SO3Na synthetic derivatives, respectively). Most complexes, except for EZT/SBE-β-CD at 1:2 or higher ratios, showed superior solubility compared with EZT powder and commercial products. Molecular docking simulations confirmed EZT inclusion within the CD, revealing hydrogen bonds and binding energies that aligned with solubility trends. These findings suggest that EZT complexes with β-CD derivatives significantly improve solubility, highlighting their potential for developing more effective oral solid formulations for hyperlipidemia treatment.
- Open Access
A Quaternary Solid Dispersion System for Improving the Solubility of Olaparib
To improve the low solubility of poorly water soluble olaparib, in the following study, we prepared olaparib-loaded quaternary solid dispersions with hypromellose, Tween 20 or Labrasol, and colloidal silica. The solubility of olaparib with various types of surfactants was evaluated to select the most suitable surfactant to effectively enhance its solubility, and subsequently, olaparib-loaded quaternary solid dispersions were prepared through spray drying. The physicochemical properties of the prepared olaparib-loaded quaternary solid dispersions were investigated using scanning electron microscopy, flowability, powder X-ray diffraction, and Fourier-transform infrared spectroscopy. The particle size of the olaparib-loaded quaternary solid dispersions was smaller and more spherical compared to the olaparib drug powder and maintained an amorphous state, and olaparib exhibited no intermolecular interactions with other excipients within the solid dispersion. Additionally, they exhibited enhanced flow properties compared to the olaparib drug powder. The results of subsequent kinetic solubility tests and dissolution tests demonstrated that the surfactant influenced the enhancement of the solubility and drug release of olaparib. Therefore, olaparib-loaded quaternary solid dispersions, characterized by enhanced solubility, will be beneficial for the oral delivery of poorly soluble olaparib.
Open AccessA Quaternary Solid Dispersion System for Improving the Solubility of Olaparib
To improve the low solubility of poorly water soluble olaparib, in the following study, we prepared olaparib-loaded quaternary solid dispersions with hypromellose, Tween 20 or Labrasol, and colloidal silica. The solubility of olaparib with various types of surfactants was evaluated to select the most suitable surfactant to effectively enhance its solubility, and subsequently, olaparib-loaded quaternary solid dispersions were prepared through spray drying. The physicochemical properties of the prepared olaparib-loaded quaternary solid dispersions were investigated using scanning electron microscopy, flowability, powder X-ray diffraction, and Fourier-transform infrared spectroscopy. The particle size of the olaparib-loaded quaternary solid dispersions was smaller and more spherical compared to the olaparib drug powder and maintained an amorphous state, and olaparib exhibited no intermolecular interactions with other excipients within the solid dispersion. Additionally, they exhibited enhanced flow properties compared to the olaparib drug powder. The results of subsequent kinetic solubility tests and dissolution tests demonstrated that the surfactant influenced the enhancement of the solubility and drug release of olaparib. Therefore, olaparib-loaded quaternary solid dispersions, characterized by enhanced solubility, will be beneficial for the oral delivery of poorly soluble olaparib.
- Open Access
Development and Characterization of Long-Acting Injectable Risperidone Microspheres Using Biodegradable Polymers: Formulation Optimization and Release Kinetics
The aim of this study was to develop a long-acting injectable formulation of risperidone using polylactic acid (PLA) or poly (lactic-co-glycolic acid) (PLGA), a biodegradable and biocompatible polymer. Risperidone microspheres (RMs) were prepared by creating an O/W emulsion using dichloromethane (DCM) as a solvent and then employing the solvent evaporation method. The RMs were prepared with four different risperidone-to-PLGA ratios (1:1, 1:1.3, 1:2, and 1:3 (w/w)), and each ratio was subjected to the same manufacturing process. The physicochemical properties of the prepared RMs, such as their shape, particle size, drug loading ratio, encapsulation efficiency, and in vitro degradation profile, were evaluated. The particle size of the RMs ranged from 30 to 100 μm, with larger PLGA ratios resulting in larger RM sizes. The drug loading ratio was inversely proportional to the increase in the PLGA ratio in the RMs, and all the formulations showed improved release profiles compared to the reference drug, Risperdal Consta®. The release data modeling results showed that the RM-3 formulation with a 1:1 (w/w) ratio of risperidone and PLGA exhibited a release pattern close to zero-order kinetics. The manufactured RMs were confirmed to have the potential to be used as a long-acting risperidone injection with sustained and stable release as well as an extended dosing interval.
Open AccessDevelopment and Characterization of Long-Acting Injectable Risperidone Microspheres Using Biodegradable Polymers: Formulation Optimization and Release Kinetics
The aim of this study was to develop a long-acting injectable formulation of risperidone using polylactic acid (PLA) or poly (lactic-co-glycolic acid) (PLGA), a biodegradable and biocompatible polymer. Risperidone microspheres (RMs) were prepared by creating an O/W emulsion using dichloromethane (DCM) as a solvent and then employing the solvent evaporation method. The RMs were prepared with four different risperidone-to-PLGA ratios (1:1, 1:1.3, 1:2, and 1:3 (w/w)), and each ratio was subjected to the same manufacturing process. The physicochemical properties of the prepared RMs, such as their shape, particle size, drug loading ratio, encapsulation efficiency, and in vitro degradation profile, were evaluated. The particle size of the RMs ranged from 30 to 100 μm, with larger PLGA ratios resulting in larger RM sizes. The drug loading ratio was inversely proportional to the increase in the PLGA ratio in the RMs, and all the formulations showed improved release profiles compared to the reference drug, Risperdal Consta®. The release data modeling results showed that the RM-3 formulation with a 1:1 (w/w) ratio of risperidone and PLGA exhibited a release pattern close to zero-order kinetics. The manufactured RMs were confirmed to have the potential to be used as a long-acting risperidone injection with sustained and stable release as well as an extended dosing interval.
- Open Access
- 21 July 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (7) , 963
Enhanced Stability and Compatibility of Montelukast and Levocetirizine in a Fixed-Dose Combination Monolayer Tablet
The purpose of this study was to enhance the stability of montelukast and levocetirizine for the development of a fixed-dose combination (FDC) monolayer tablet. To evaluate the compatibility of montelukast and levocetirizine, a mixture of the two drugs was prepared, and changes in the appearance characteristics and impurity content were observed in a dry oven at 60 °C. Excipients that contributed minimally to impurity increases were selected to minimize drug interactions. Mannitol, microcrystalline cellulose, croscarmellose sodium, hypromellose, and sodium citrate were chosen as excipients, and montelukast–levocetirizine FDC monolayer tablets were prepared by wet granulating the two drugs separately. A separate granulation of montelukast and levocetirizine, along with the addition of sodium citrate as a pH stabilizer, minimized the changes in tablet appearance and impurity levels. The prepared tablets demonstrated release profiles equivalent to those of commercial products in comparative dissolution tests. Subsequent stability testing at 40 ± 2 °C and 75 ± 5% RH for 6 months confirmed that the drug content, dissolution rate, and impurity content met the specified acceptance criteria. In conclusion, the montelukast–levocetirizine FDC monolayer tablet developed in this study offers a potential alternative to commercial products.
- 21 July 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (7) , 963
Open AccessEnhanced Stability and Compatibility of Montelukast and Levocetirizine in a Fixed-Dose Combination Monolayer Tablet
The purpose of this study was to enhance the stability of montelukast and levocetirizine for the development of a fixed-dose combination (FDC) monolayer tablet. To evaluate the compatibility of montelukast and levocetirizine, a mixture of the two drugs was prepared, and changes in the appearance characteristics and impurity content were observed in a dry oven at 60 °C. Excipients that contributed minimally to impurity increases were selected to minimize drug interactions. Mannitol, microcrystalline cellulose, croscarmellose sodium, hypromellose, and sodium citrate were chosen as excipients, and montelukast–levocetirizine FDC monolayer tablets were prepared by wet granulating the two drugs separately. A separate granulation of montelukast and levocetirizine, along with the addition of sodium citrate as a pH stabilizer, minimized the changes in tablet appearance and impurity levels. The prepared tablets demonstrated release profiles equivalent to those of commercial products in comparative dissolution tests. Subsequent stability testing at 40 ± 2 °C and 75 ± 5% RH for 6 months confirmed that the drug content, dissolution rate, and impurity content met the specified acceptance criteria. In conclusion, the montelukast–levocetirizine FDC monolayer tablet developed in this study offers a potential alternative to commercial products.
- Open Access
- 26 March 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 457
The Impact of Polymers on Enzalutamide Solid Self-Nanoemulsifying Drug Delivery System and Improved Bioavailability
Enzalutamide (ENZ), marketed under the brand name Xtandi® as a soft capsule, is an androgen receptor signaling inhibitor drug actively used in clinical settings for treating prostate cancer. However, ENZ’s low solubility and bioavailability significantly hinder the achievement of optimal therapeutic outcomes. In previous studies, a liquid self-nanoemulsifying drug delivery system (L-SNEDDS) containing ENZ was developed among various solubilization technologies. However, powder formulations that included colloidal silica rapidly formed crystal nuclei in aqueous solutions, leading to a significant decrease in dissolution. Consequently, this study evaluated the efficacy of adding a polymer as a recrystallization inhibitor to a solid SNEDDS (S-SNEDDS) to maintain the drug in a stable, amorphous state in aqueous environments. Polymers were selected based on solubility tests, and the S-SNEDDS formulation was successfully produced via spray drying. The optimized S-SNEDDS formulation demonstrated through X-ray diffraction and differential scanning calorimetry data that it significantly reduced drug crystallinity and enhanced its dissolution rate in simulated gastric and intestinal fluid conditions. In an in vivo study, the bioavailability of orally administered formulations was increased compared to the free drug. Our results highlight the effectiveness of solid-SNEDDS formulations in enhancing the bioavailability of ENZ and outline the potential translational directions for oral drug development.
- 26 March 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 457
Open AccessThe Impact of Polymers on Enzalutamide Solid Self-Nanoemulsifying Drug Delivery System and Improved Bioavailability
Enzalutamide (ENZ), marketed under the brand name Xtandi® as a soft capsule, is an androgen receptor signaling inhibitor drug actively used in clinical settings for treating prostate cancer. However, ENZ’s low solubility and bioavailability significantly hinder the achievement of optimal therapeutic outcomes. In previous studies, a liquid self-nanoemulsifying drug delivery system (L-SNEDDS) containing ENZ was developed among various solubilization technologies. However, powder formulations that included colloidal silica rapidly formed crystal nuclei in aqueous solutions, leading to a significant decrease in dissolution. Consequently, this study evaluated the efficacy of adding a polymer as a recrystallization inhibitor to a solid SNEDDS (S-SNEDDS) to maintain the drug in a stable, amorphous state in aqueous environments. Polymers were selected based on solubility tests, and the S-SNEDDS formulation was successfully produced via spray drying. The optimized S-SNEDDS formulation demonstrated through X-ray diffraction and differential scanning calorimetry data that it significantly reduced drug crystallinity and enhanced its dissolution rate in simulated gastric and intestinal fluid conditions. In an in vivo study, the bioavailability of orally administered formulations was increased compared to the free drug. Our results highlight the effectiveness of solid-SNEDDS formulations in enhancing the bioavailability of ENZ and outline the potential translational directions for oral drug development.